Background: There have been a few reports of hypersensitivity reactions to Ranitidine and cross-reactivities between H2-receptor antagonists. The pathogenic mechanisms of H2 receptor antagonist induced hypersensitivity reactions are not understood. The purpose of this study was to observe the clinical characteristics of the patients with Ranitidine anaphylaxis and investigate the pathogenic mechanisms with detection of serum specific IgE antibody to Ranitidine-HSA conjugate. Methods: Ten patients with anaphylaxis to Ranitidine were enrolled from Ajou University Hospital and Seoul National University Bundang Hospital. Skin prick test (SPT) using Ranitidine extract were performed in 7 patients. Serum specific IgE and G1 antibodies were detected by ELISA using Ranitidine-HSA conjugate. The study subjects were divided into 2 groups according to the presence of serum specific IgE antibody to Ranitidine-HSA conjugate: 3 subjects had high serum specific IgE (Group I) and 7 subjects showed negative results (Group II), when positive cut off value was determined from mean 1 3 SD of absorbance values of healthy controls. Results: Six (60%) were female and 9 (90%) were atopics. 6 (86%) patients had positive responses to ranitidine on SPT, however, high serum specific IgE to Ranitidine-HSA conjugate was detected in only 3 patients (30%), while serum specific IgG1 was detectable in one patient (10%). There were no significant differences in clinical characteristics including age, sex, atopy and serum total IgE level between group I and II. Conclusions: We confirmed the presence of serum specific IgE to Ranitidine-HSA conjugate by ELISA, suggesting that IgE mediated response is a major pathogenic mechanism of Ranitidine induced anaphylaxis. Further studies will be needed to investigate other immunologic and non-immunologic mechanisms and cross-reactivity among other H2 receptor antagonists. Methods: This is a retrospective study of SRs to optimal dose SCIT with any combination of approximately 20 allergens (pollens, animal emanations, molds, and Hymenoptera) in 840 subjects representing 13,812 encounters over 12 months (June 2010-May 2011. Nurses administered stat epi IM (1:1000 v/v), 0.2 mg, immediately into the arm or thigh for any systemic signs or symptoms (SS) of a SR, including, but not limited to, itchy eyes, nose, pharynx, palms; rhinorrhea, nasal congestion, sneezing; and generalized erythema, pruritus, or urticaria. Repeat doses of epi IM were administered as necessary. Results: 32 subjects (3.8%) each had one SR: 21 (66%) Grade 1, 10 (31%) Grade 2, 1 (3%) Grade 3, and Grades 4 or 5. BMIs were missing in 3 subjects. Fifteen of 29 were in the normal weight range (BMI 18.5-24.9), 9 Grade 1 (mean epi IM, 0.27 mg) and 6 Grade 2 (mean epi IM, 0.3 mg). Mean epi IM was 0.28 mg. Eight of 29 subjects were overweight Background: Both eperisone and afloqualone act by relaxing both skeletal muscles and vascular smooth muscles to improve circulation and suppress pain reflex. These drugs are usually prescribed combined with non-steroid anti-inflammatory drugs (NSAIDs) as pain killers. Although there have been no report on serious adverse reactions to muscle relaxant, this is the first report of 3 anaphylactic reactions caused by eperisone and afloqualone. Methods: All 3 patients had previous histories of anaphylaxis after oral intake of multiple pain killers including muscle relaxant and NSAID for chronic muscle pain. Open label oral challenge tests were performed with each drug to find out which drugs caused systemic reactions. Results: All experienced the same reactions within an hour after oral intake of eperisone or afloqualone. The severity of these reactions ranged from laryngeal edema to hypotension. To confirm the systemic reaction caused by eperisone or afloqualone, skin prick testing and intradermal skin tests with eperisone or afloqualone extract were performed in vivo, and the basophil activity tests were performed with stimulation with these drugs in vitro. In one patient with laryngeal edema, intradermal test with afloqualone results showed positive result and CD63 level increased after the stimulation with afloqualone dose-dependently. Conclusions: We report 3 allergic reactions caused by oral muscle relaxants that might be mediated by non-IgE-mediated responses. As muscle relaxant, eperisone and afloqualone, commonly prescribed drugs for chronic muscle pain, can induce severe allergic reactions therefore we should prescribe them carefully.
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